Halozyme Therapeutics | HALO - 债务



金融业
股票价格
USD
资产
USD 2.53B
现金及等价物
USD 133.82M
销售成本
USD 102.15M
流动资产
USD 825.21M
流动负债
USD 177.09M
债务
USD 1.51B
EBIT
USD -88.41M
EBITDA
USD 21.9M
员工
350
EPS每股收益
USD -0.24
股本和储备
USD 48.81M
销售毛利
USD 281.77M
债务利息支出
USD 4.91M
贷款资金
USD 2.14B
市值
USD 8.19B
净收入
USD -141.59M
营业费用
USD 211.07M
营业利润
USD -88.41M
普通股股本
USD 117.78M
PE价格收益
23.16
税前利润
USD 218.96M
销售收入
USD 451.76M
销售和管理费用
USD 64.64M
股票
USD 176.48M
贸易债权人
USD 20.9M
应收帐款人
USD 441.27M


债务 更改 日
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amarin USD 0 0 2025-03
Amgen USD 54.59B 1.62B 2025-09
Baxter International USD 9.71B 13M 2025-09
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.2B 338.79M 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
MannKind USD 119.91M 73.09M 2025-09
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Pfizer USD 60.85B 78M 2025-09
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12